FOLD Overview

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is14.79 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Amicus Therapeutics Inc revenue for the last quarter amounts to 185.21M USD, increased 23.72

Amicus Therapeutics Inc. EPS for the last quarter amounts to 0.01 USD, decreased -80.00

Amicus Therapeutics Inc (FOLD) has 511 emplpoyees as of March 12 2026.

Today FOLD has the market capitalization of 4.51B USD.